
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models
Keywords: Istradefylline; KW-6002; Parkinson's disease; l-DOPA-induced dyskinesia; Cognition; MPTP; CLD; Chronic low dose; CPT; Continuous performance task; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NHP; Non-human primate; PD; Parkinson's disease; LID;